Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies

Journal of Immunological Methods

Volumn 414, Issue , 2014, Pages 69-81

  Cheng, Zhijie Jey ^a   Garvin, Denise ^a   Paguio, Aileen ^a   Moravec, Richard ^a   Engel, Laurie ^a   Fan, Frank ^a   Surowy, Teresa ^a  

^a PROMEGA CORPORATION   (United States)

Author keywords

ADCC reporter assay; Antibody dependent cell mediated cytotoxicity; Fc effector function; Fc RIIIa; Monoclonal therapeutic antibody

Indexed keywords

CD20 ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR; PANITUMUMAB; RITUXIMAB; TRASTUZUMAB; ANTIBODY; CD20 ANTIGEN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FCGR3A PROTEIN, HUMAN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ADCC ASSAY; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DEGLYCOSYLATION; DRUG CYTOTOXICITY; EC50; EFFECTOR CELL; FLUORESCENCE ACTIVATED CELL SORTING; FREEZE THAWING; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOASSAY; JURKAT CELL LINE; LUCIFERASE ASSAY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; ANTAGONISTS AND INHIBITORS; CYTOTOXICITY TEST; IMMUNOLOGY; MCF 7 CELL LINE; TUMOR CELL LINE;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; JURKAT CELLS; MCF-7 CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG;

EID: 84914152611     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.07.010     Document Type: Article

References (52)

1. Azzoni L., Kamoun M., Salcedo T.W., Kanakaraj P., Perussia B. Stimulation of Fc gamma RIIIA results in phospholipase C-gamma 1 tyrosine phosphorylation and p56lck activation. J. Exp. Med. 1992, 176:1745.
2. Beck A., Wagner-Rousset E., Bussat M.C., Lokteff M., Klinguer-Hamour C., Haeuw J.F., Goetsch L., Wurch T., Van Dorsselaer A., Corvaia N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol. 2008, 9:482.
3. Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S., Weiner L.M. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J. Immunol. 2008, 180:6392.
4. 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 1968, 14:181.
5. Buttner F.H. Cell-based assays for high-throughput screening. Expert Opin. Drug Discovery 2006, 1:373.
6. Cardarelli P.M., Quinn M., Buckman D., Fang Y., Colcher D., King D.J., Bebbington C., Yarranton G. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol. Immunother. 2002, 51:15.
7. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4285.
8. Chan A.C., Carter P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 2010, 10:301.
9. Cheng Z., Garvin D., Paguio A., Stecha P., Wood K., Fan F. Luciferase reporter assay system for deciphering GPCR pathways. Curr. Chem. Genomics 2010, 4:84.
10. Chung S., Quarmby V., Gao X., Ying Y., Lin L., Reed C., Fong C., Lau W., Qiu Z.J., Shen A., et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs 2012, 4:326.
11. Chung S., Lin Y.L., Reed C., Ng C., Cheng Z.J., Malavasi F., Yang J., Quarmby V., Song A. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells. J. Immunol. Methods 2014, 407:63.
12. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004, 64:4664.
13. Dhupkar P., Dowling M., Cengel K., Chen B. Effects of anti-EGFR antibody cetuximab on androgen-independent prostate cancer cells. Anticancer Res. 2010, 30:1905.
14. Fanger M.W., Graziano R.F., Shen L., Guyre P.M. Fc gamma R in cytotoxicity exerted by mononuclear cells. Chem. Immunol. 1989, 47:214.
15. Fanger M.W., Shen L., Graziano R.F., Guyre P.M. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today 1989, 10:92.
16. Fursov N., Cong M., Federici M., Platchek M., Haytko P., Tacke R., Livelli T., Zhong Z. Improving consistency of cell-based assays by using division-arrested cells. Assay Drug Dev. Technol. 2005, 3:7.
17. Gazzano-Santoro H., Chen A., Casto B., Chu H., Gilkerson E., Mukku V., Canova-Davis E., Kotts C. Validation of a rat pheochromocytoma (PC12)-based cell survival assay for determining biological potency of recombinant human nerve growth factor. J. Pharm. Biomed. Anal. 1999, 21:945.
18. Gong J.H., Maki G., Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994, 8:652.
19. Graziano R.F., Looney R.J., Shen L., Fanger M.W. Fc gamma R-mediated killing by eosinophils. J. Immunol. 1989, 142:230.
20. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.Y., Ultsch M., Meng Y.G., Mulkerrin M.G. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 2000, 164:4178.
21. Jiang X.R., Song A., Bergelson S., Arroll T., Parekh B., May K., Chung S., Strouse R., Mire-Sluis A., Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 2011, 10:101.
22. Kimura H., Sakai K., Arao T., Shimoyama T., Tamura T., Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007, 98:1275.
23. Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E., de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997, 90:1109.
24. Korzeniewski C., Callewaert D.M. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 1983, 64:313.
25. Lallemand C., Kavrochorianou N., Steenholdt C., Bendtzen K., Ainsworth M.A., Meritet J.F., Blanchard B., Lebon P., Taylor P., Charles P., et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J. Immunol. Methods 2011, 373:229.
26. Leader B., Baca Q.J., Golan D.E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 2008, 7:21.
27. Leibson P.J. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 1997, 6:655.
28. Lewis T.S., McCormick R.S., Emmerton K., Lau J.T., Yu S.F., McEarchern J.A., Grewal I.S., Law C.L. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin. Cancer Res. 2011, 17:4672.
29. Lyubchenko T.A., Wurth G.A., Zweifach A. Role of calcium influx in cytotoxic T lymphocyte lytic granule exocytosis during target cell killing. Immunity 2001, 15:847.
30. Moingeon P., Lucich J.L., McConkey D.J., Letourneur F., Malissen B., Kochan J., Chang H.C., Rodewald H.R., Reinherz E.L. CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:1492.
31. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34.
32. Parekh B.S., Berger E., Sibley S., Cahya S., Xiao L., LaCerte M.A., Vaillancourt P., Wooden S., Gately D. Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs 2012, 4:310.
33. Patel A.K., Boyd P.N. An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. J. Immunol. Methods 1995, 184:29.
34. Patel D., Guo X., Ng S., Melchior M., Balderes P., Burtrum D., Persaud K., Luna X., Ludwig D.L., Kang X. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum. Antibodies 2010, 19:89.
35. Prang N., Preithner S., Brischwein K., Goster P., Woppel A., Muller J., Steiger C., Peters M., Baeuerle P.A., da Silva A.J. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br. J. Cancer 2005, 92:342.
36. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435.
37. Reim F., Dombrowski Y., Ritter C., Buttmann M., Hausler S., Ossadnik M., Krockenberger M., Beier D., Beier C.P., Dietl J., et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res. 2009, 69:8058.
38. Robertson M.J., Cochran K.J., Cameron C., Le J.M., Tantravahi R., Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 1996, 24:406.
39. Roden M.M., Lee K.H., Panelli M.C., Marincola F.M. A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J. Immunol. Methods 1999, 226:29.
40. Rukenstein A., Greene L.A. The quantitative bioassay of nerve growth factor: use of frozen 'primed' PC12 pheochromocytoma cells. Brain Res. 1983, 263:177.
41. Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S., Zocher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol. Immunol. 2011, 48:1512.
42. Sergeeva A., Alatrash G., He H., Ruisaard K., Lu S., Wygant J., McIntyre B.W., Ma Q., Li D., St John L., et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011, 117:4262.
43. Siberil S., Dutertre C.A., Fridman W.H., Teillaud J.L. FcgammaR: The key to optimize therapeutic antibodies?. Crit. Rev. Oncol. Hematol. 2007, 62:26.
44. Stewart R., Thom G., Levens M., Guler-Gane G., Holgate R., Rudd P.M., Webster C., Jermutus L., Lund J. A variant human IgG1-Fc mediates improved ADCC. Protein Eng. Des. Sel. 2011, 24:671.
45. Strong D.M., Ortaldo J.R., Pandolfi F., Maluish A., Herberman R.B. Cryopreservation of human mononuclear cells for quality control in clinical immunology. I. Correlations in recovery of K- and NK-cell functions, surface markers, and morphology. J. Clin. Immunol. 1982, 2:214.
46. Suzuki E., Niwa R., Saji S., Muta M., Hirose M., Iida S., Shiotsu Y., Satoh M., Shitara K., Kondo M., et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin. Cancer Res. 2007, 13:1875.
47. TerWee J.A., Chin C.L., Watrin S., Tello R.F., Rieder N.J., Lowell J.D., Latham-Timmons D. Increased consistency and efficiency in routine potency testing by bioassay with direct use of cryopreserved (ready-to-plate) cells. J. Immunol. Methods 2011, 370:65.
48. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359:1116.
49. Vivier E., Rochet N., Ackerly M., Petrini J., Levine H., Daley J., Anderson P. Signaling function of reconstituted CD16: zeta: gamma receptor complex isoforms. Int. Immunol. 1992, 4:1313.
50. von Zons P., Crowley-Nowick P., Friberg D., Bell M., Koldovsky U., Whiteside T.L. Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma. Clin. Diagn. Lab. Immunol. 1997, 4:202.
51. Wirthmueller U., Kurosaki T., Murakami M.S., Ravetch J.V. Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain. J. Exp. Med. 1992, 175:1381.
52. Zaman G.J., de Roos J.A., Blomenrohr M., van Koppen C.J., Oosterom J. Cryopreserved cells facilitate cell-based drug discovery. Drug Discov. Today 2007, 12:521.